Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Long-Term Debt Repayments (2022 - 2025)

Historic Long-Term Debt Repayments for SAB Biotherapeutics (SABS) over the last 4 years, with Q3 2025 value amounting to $3.0.

  • SAB Biotherapeutics' Long-Term Debt Repayments fell 9999.95% to $3.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $515982.0, marking a year-over-year decrease of 6051.68%. This contributed to the annual value of $1.3 million for FY2024, which is 2550.21% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Long-Term Debt Repayments of $3.0 as of Q3 2025, which was down 9999.95% from $138551.0 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Long-Term Debt Repayments peaked at $761050.0 during Q2 2022, and registered a low of $3.0 during Q3 2025.
  • Moreover, its 4-year median value for Long-Term Debt Repayments was $254913.0 (2022), whereas its average is $323711.2.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first surged by 45036.33% in 2024, then tumbled by 9999.95% in 2025.
  • Over the past 4 years, SAB Biotherapeutics' Long-Term Debt Repayments (Quarter) stood at $488437.0 in 2022, then tumbled by 47.59% to $255989.0 in 2023, then decreased by 6.19% to $240133.0 in 2024, then crashed by 100.0% to $3.0 in 2025.
  • Its Long-Term Debt Repayments was $3.0 in Q3 2025, compared to $138551.0 in Q2 2025 and $137295.0 in Q1 2025.